

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

Recombinant Anti-Granzyme B antibody [EPR22645-206]

RRID:AB_2860567

Type: Antibody

Proper Citation

Abcam Cat# ab255598, RRID:AB_2860567

Antibody Information

URL: http://antibodyregistry.org/AB_2860567

Proper Citation: Abcam Cat# ab255598, RRID:AB_2860567

Target Antigen: Granzyme B

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IHC-P, IHC-Fr, IP

Antibody Name: Recombinant Anti-Granzyme B antibody [EPR22645-206]

Description: This recombinant targets Granzyme B

Target Organism: Human, Mouse

Clone ID: EPR22645-206

Antibody ID: AB_2860567

Vendor: Abcam

Catalog Number: ab255598

Record Creation Time: 20250820T004107+0000

Record Last Update: 20250820T085515+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Granzyme B antibody [EPR22645-206].

No alerts have been found for Recombinant Anti-Granzyme B antibody [EPR22645-206].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. *Cancer cell*.

Li X, et al. (2025) The Dynamically Evolving Cell States and Ecosystem from Benign Nevi to Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(12), 2478.

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. *Immunity*, 58(6), 1502.

Zhou Q, et al. (2025) Vorapaxar enhanced mitochondria-associated ferroptosis primes cancer immunotherapy via targeting FOXO1/HMOX1 axis. *Cell reports. Medicine*, 102371.

Xu Y, et al. (2025) Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. *Cell*.

Wang M, et al. (2025) Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. *Cancer discovery*, 15(9), 1883.

Chen D, et al. (2025) Ce6 derivative photodynamic therapy triggers PANoptosis and enhances antitumor immunity with LAG3 blockade in cutaneous squamous cell carcinoma. *Cell reports. Medicine*, 6(7), 102239.

Tang R, et al. (2025) Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. *Gastroenterology*, 169(4), 615.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. *Cell reports*, 44(11), 116526.

Kim S, et al. (2025) Multiregional single-cell transcriptomics reveals an association between partial EMT and immunosuppressive states in oral squamous cell carcinoma. *iScience*, 28(9), 112988.

Zhong L, et al. (2025) Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. *Cell*, 188(4), 1119.

Yang S, et al. (2025) LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1/LTBP1/TGF- β axis. *Cell reports. Medicine*, 6(3), 102000.

Liu Y, et al. (2025) Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. *Cell metabolism*, 37(9), 1907.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8⁺ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

Zhu R, et al. (2024) ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. *Cell metabolism*.

Wang X, et al. (2024) *Fusobacterium nucleatum* facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. *Cancer cell*, 42(10), 1729.

Franzolin G, et al. (2024) PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination. *Cancer immunology research*, 12(9), 1286.

Liu X, et al. (2023) Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. *Cancer cell*, 41(2), 272.

Tang R, et al. (2023) Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. *Cell reports. Medicine*, 4(10), 101234.

Tian T, et al. (2023) FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancer immunity and suppress inflammation. *Cell reports*, 42(11), 113362.